Contineum Therapeutics, Inc. Balance Sheet
CTNM|1 years of annual SEC 10-K data (FY2024-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity. All figures from audited SEC 10-K filings.
Contineum Therapeutics, Inc. had $213M in total assets and $198M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.08 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Cash & Equivalents | $21.9M |
| Current Assets | $206.4M |
| PP&E (Net) | $989.0K |
| Total Assets | $212.8M |
| Current Liabilities | $10.0M |
| Shareholders' Equity | $198.1M |